[go: up one dir, main page]

MX2010006260A - Composiciones orales de abt-263 para tratar cancer. - Google Patents

Composiciones orales de abt-263 para tratar cancer.

Info

Publication number
MX2010006260A
MX2010006260A MX2010006260A MX2010006260A MX2010006260A MX 2010006260 A MX2010006260 A MX 2010006260A MX 2010006260 A MX2010006260 A MX 2010006260A MX 2010006260 A MX2010006260 A MX 2010006260A MX 2010006260 A MX2010006260 A MX 2010006260A
Authority
MX
Mexico
Prior art keywords
treating cancer
abt
oral compositions
methyl
phenylsulfanyl
Prior art date
Application number
MX2010006260A
Other languages
English (en)
Inventor
Andrew Krivoshik
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010006260A publication Critical patent/MX2010006260A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para el tratamiento de cáncer utilizando N-(4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil )piperazin-1-il)benzoil)-4-(((1R)-3-(morfolin-4-iI)-1-((fenilsulf anil)-metil)propil)amino)-3-((trifluorometil)sulfonil)bencensulfo namida.
MX2010006260A 2007-12-06 2008-12-05 Composiciones orales de abt-263 para tratar cancer. MX2010006260A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99285707P 2007-12-06 2007-12-06
US5811308P 2008-06-02 2008-06-02
PCT/US2008/085628 WO2009073835A1 (en) 2007-12-06 2008-12-05 Oral compositions of abt-263 for treating cancer

Publications (1)

Publication Number Publication Date
MX2010006260A true MX2010006260A (es) 2010-08-23

Family

ID=40262293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006260A MX2010006260A (es) 2007-12-06 2008-12-05 Composiciones orales de abt-263 para tratar cancer.

Country Status (7)

Country Link
US (1) US20090149461A1 (es)
EP (1) EP2219651A1 (es)
JP (1) JP2011506338A (es)
CN (1) CN101939008A (es)
CA (1) CA2708223A1 (es)
MX (1) MX2010006260A (es)
WO (1) WO2009073835A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
RU2012101627A (ru) * 2009-06-18 2013-07-27 Эбботт Лэборетриз Стабильная суспензия лекарственного средства в виде наночастиц
KR20120085781A (ko) 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
AU2010336518B2 (en) 2009-12-22 2014-03-06 Abbvie Inc. ABT-263 capsule
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
UY33746A (es) 2010-11-23 2012-06-29 Abbott Lab Método de tratamiento que usa inhibidores selectivos de bcl-2
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015007714A1 (en) * 2013-07-17 2015-01-22 Deutsches Krebsforschungszentrum Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EP3708170A1 (en) 2014-05-05 2020-09-16 BioVentures, LLC Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606147C (en) * 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters

Also Published As

Publication number Publication date
US20090149461A1 (en) 2009-06-11
CA2708223A1 (en) 2009-06-11
JP2011506338A (ja) 2011-03-03
EP2219651A1 (en) 2010-08-25
WO2009073835A1 (en) 2009-06-11
CN101939008A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
MX2010006260A (es) Composiciones orales de abt-263 para tratar cancer.
CY1114242T1 (el) Μια διεργασια για την παρασκευη του υποκινητη αποπτωσης αβτ-263
NZ598461A (en) Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
NZ585085A (en) Method of treating arthritis using arylsulfonamide compounds
AR109816A2 (es) Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2
PE20191108A1 (es) Inhibidores selectivos de jak1
NZ593594A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EA201290255A1 (ru) Способы и композиции для лечения рака
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
NZ603525A (en) Pyrimidine based compound and uses thereof
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ597647A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
EA201001269A1 (ru) Соли (е)-n-(2-аминофенил)-3-{1-[4-(1-метил-1h-пиразол-4-ил)бензолсульфонил]-1h-пиррол-3-ил}акриламида
IL199403A0 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
DOP2011000325A (es) Composición farmacéutica en forma de una solución líquida que comprende n- (4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4- (((1r)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino-3-((trifluorometil) sulfonil)bencenosulfonamida (abt-263)
DE602006012713D1 (de) Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4)
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
TW200616965A (en) Synthesis of n2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.